Recent progress in nanoformulations of cabazitaxel

Area of Science:

• Oncology
• Nanomedicine
• Drug Delivery Systems

Background:

• Paclitaxel and docetaxel resistance limits their antitumor efficacy.
• Cabazitaxel, a second-generation taxane, demonstrates superior anticancer activity and low P-glycoprotein affinity.
• Current cabazitaxel use is restricted by toxicity, hydrophobicity, and formulation instability.

Purpose of the Study:

• To review recent advancements in cabazitaxel drug delivery systems.
• To summarize challenges in developing cabazitaxel nanoformulations.
• To propose strategies for overcoming these challenges in nanomedicine.

Main Methods:

• Literature review of recent publications on cabazitaxel nanomedicine.
• Analysis of drug delivery systems for cabazitaxel.
• Identification of challenges and proposed solutions for nanoformulation development.

Main Results:

• Various nanomedicine approaches are being investigated for cabazitaxel delivery.
• Key challenges include cabazitaxel's inherent properties and formulation stability.
• Strategies focus on enhancing delivery and overcoming resistance mechanisms.

Conclusions:

• Nanomedicine holds significant potential to overcome cabazitaxel limitations and taxane resistance.
• Further research into optimized nanoformulations is crucial for clinical translation.
• Developing stable and effective cabazitaxel nanoformulations can expand its therapeutic applications.